|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 11, 2021 ) According to the new market research report the leukemia therapeutics market is projected to reach USD 17.1 billion by 2024 from USD 12.3 billion in 2019, at a CAGR of 6.8% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223
Leukemia is a type of cancer originating from white blood cells or the bone marrow, which occurs due to an abnormal increase in the count of white blood cells. It is identified by the spread of the disease (either acute or chronic), and by the type of the blood cell that is affected (lymphocytic or myeloid). The treatment options depend on several factors, including the phase of the disease, possible side effects, and the patient’s overall health. Leukemia therapeutic drugs are used to destroy cancer cells. This type of medication is given through the bloodstream to reach cancer cells throughout the body.
Premium Insights
> Leukemia Therapeutics: Market Overview
> Leukemia Therapeutics Market, By Treatment Type & Mode of Administration (2019)
> Geographical Snapshot of the Leukemia Therapeutics Market
In 2018, the small molecules segment accounted for the largest market share. This is mainly attributed to the availability of a large number of chemo and targeted drugs—which are small molecules. A large number of small-molecule drugs have also been approved, which is expected to drive the market growth.
The chronic myeloid leukemia segment is anticipated to account for the largest market share. The high incidence rate of chronic myeloid leukemia and the large number of treatment options available are the major factors driving the growth of this market segment. In the US, nearly 15% of the newly diagnosed cases of leukemia are CML. Nearly 1 person in 526 is diagnosed with CML in the US.
The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland, F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.
Recent Developments:
> In January 2019, the EU approved BLINCYTO (blinatumomab) in patients with Philadelphia chromosome negative minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia. BLINCYTO is the first and only therapy for a minimal residual disease that has been approved by the EU.
> In September 2018, blinatumomab received approval in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
> In July 2017, Celgene Corporation entered into a strategic partnership to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317, for patients with solid tumor cancers. In addition to it, BeiGene acquired Celgene's commercial operations in China and gained an exclusive license to commercialize Celgene China’s cancer portfolio, inclusive of Vidaza.
Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=223
The North American market is expected to account for the largest share, globally. The rising number of leukemia patients, tissue engineering, new drugs & therapies launches, and high research funding for the treatment of leukemia are the major driving factors in this market. In 2018, according to the Leukemia & Lymphoma Society, an estimated 381,774 people were living with or in remission from leukemia in the US. According to the Canadian Cancer Society, nearly 138,100 people in Canada are living with or are in remission from blood cancer (data as of 2016). In addition, nearly 22,340 Canadians of all ages were diagnosed with a form of blood cancer, including 5,900 cases of leukemia.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
